The European Sperm Bank (ESB), one of the largest sperm banks globally, is under scrutiny after Danish authorities filed a police report regarding sperm from a donor known as “Kjeld” containing a cancer-causing gene. The report comes after an extensive investigation into the donor’s sperm, which had been sold to Sweden and other European countries. The development highlights the critical issue of safety and transparency within the global fertility sector.
The report was filed by Denmark’s Patient Safety Authority (STPS), which has refrained from disclosing the reasons behind the investigation. STPS’s unit head, Bente Møller, stated that it is now up to the police to decide how to proceed with the case. “We will, of course, follow this case to the end,” Møller added, emphasizing the need for rigorous safety standards for families seeking fertility treatment in Denmark.
The case first came to light after an international investigation led by the European Broadcasting Union’s (EBU) investigative journalism network, which includes Sweden’s SVT. According to the investigation, at least 197 children were conceived using sperm from the Danish donor, Kjeld, who had donated sperm for 17 years at ESB. It was later discovered that some of his sperm carried a genetic mutation that increased the risk of cancer in his biological children.
Kjeld’s sperm was sold to 14 European countries, and several of his donor children have been diagnosed with cancer, with some even succumbing to the disease. The impact has been particularly significant in Sweden, where at least 22 children have been born using his sperm.
The European Sperm Bank has responded to the allegations, attributing the widespread use of Kjeld’s sperm to several factors, including poor reporting practices by clinics, inadequate tracking systems, and the phenomenon of “fertility tourism.” The ESB has acknowledged these issues but insists that it is committed to ensuring the safety of all donors and recipients moving forward.
This case raises important questions about the regulation and oversight of sperm banks, particularly those operating across multiple countries. It also highlights the ethical responsibility of sperm banks to ensure that their donors are thoroughly screened for genetic risks and that their sperm is not overused or misused in ways that could compromise the health of donor children.
As the investigation unfolds, the European Sperm Bank faces increasing pressure to implement stronger safeguards and more robust oversight to protect families seeking fertility treatments. Danish authorities, for their part, have pledged to continue monitoring the case closely and ensure that such an incident does not occur again.
The incident also serves as a wake-up call to the fertility industry at large, reinforcing the need for transparency, rigorous testing, and accountability in order to restore public trust and ensure the safety of all parties involved.